Technology
Information Technology
Software Service

Omnicell

$79.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.22 (-0.28%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Omnicell and other stocks, options, ETFs, and crypto commission-free!

About

Omnicell, Inc. engages in the provision of medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions. It operates through Automation & Analytics and Medication Adherence segments. Read More The Automation & Analytics segment designs, manufactures, and sells medication and supply dispensing systems, pharmacy inventory management systems, and related software. The Medication Adherence segment develops, manufactures and sells solutions to assist patients in becoming and remaining adherent to their medication regimens. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Employees
2,480
Headquarters
Mountain View, California
Founded
1992
Market Cap
3.23B
Price-Earnings Ratio
86.63
Dividend Yield
0.00
Average Volume
349.36K
High Today
$80.11
Low Today
$77.87
Open Price
$79.70
Volume
113.62K
52 Week High
$86.87
52 Week Low
$41.59

Collections

Technology
Information Technology
Software Service
US
North America

News

TradingNewsNowMar 22

Stock to Watch: Omnicell (NASDAQ: OMCL)

Omnicell is part of the technology sector and is part of the application software industry. The company CEO is Randall A. Lipps. Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing. Previous Intraday Trading Performance: The OMCL stock showed a previous change of 2.40% with an open at 82.33 and a close of 84.77. It reached ...

28
Yahoo FinanceMar 18

Omnicell's Global Expansion on Track, Stiff Competition Ails

On Mar 15, we issued an updated research report on Omnicell, Inc. OMCL. The company has laid out its strategy of expanding into new markets. This tactical move has so far been driving significant growth in the Non-Acute Care segment. However, a tough competitive landscape is a dampener. This developer and marketer of end-to-end automation solutions for the medication-use process has outperformed its industry over the past six months. The stock has rallied 23.3% against the industry’s 9.6% decline. Notably...

32
Yahoo FinanceMar 9

Omnicell (OMCL) Up 27.9% Since Last Earnings Report: Can It Continue?

Omnicell (OMCL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. It has been about a month since the last earnings report for Omnicell (OMCL). Shares have added about 27.9% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Omnicell due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most rece...

21

Earnings

$0.23
$0.39
$0.54
$0.70
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.